

IN THE CLAIMS:

Please amend the claims as follows:

Claim 14, line 1, delete "cataract-like disorders" and replace with - - after-cataract formation - -.

34. (Amended) The method of use of inhibitors of TGF β in the manufacture and ophthalmological formulation for preventing or controlling cataract or after-cataract formation [cataract-like disorders].

REMARKS

This paper is responsive to the Office action dated July 17, 1998, and is believed to place the application in condition for allowance. By this response, the claims have been amended to more particularly point out and distinctively claim Applicants' invention. Claims 14-28 and 34-38 remain pending.

In response to the Section 112, first paragraph rejection of claims 34-38, the Applicants have amended claim 34 to recite "the method of use." As amended, it is believed that these claims now satisfy the requirements of Section 112.

Concerning the Section 112, first paragraph rejection of claims 14-28, it is respectfully submitted that the claims as amended are supported by the specification of the subject